Swedish monitoring systems developer Senzime has started a clinical study of its CliniSenz System for monitoring the lactate levels in patients who have undergone surgery for esophageal cancer.

CliniSenz System is a combination of the firm’s CliniSenz Analyser and OnZurf Probe.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CliniSenz Analyser allows remote patient monitoring, needs a small volume of samples for analysis and can be used for early identification of complications and diagnosis.

Compatible with microdialysis catheters such as OnZurf Probe, the analyser features an enzyme-based heat flow detection incorporated on a microfluidic chip, which aids in avoiding substance interferences.

Designed for continuous sampling and collection of biomarkers, Onzurf Probe comes with an attachment site, which enables placement on the surface of an organ without penetration or pressure.

The microdialysis sampler can be used with analytical systems such as Clinisenz Analyser and high-performance liquid chromatography (HPLC).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Senzime CEO Lena Söderström said: “The clinical market is looking for systems that allow continuous monitoring of biomarkers in blood and tissues to rapidly detect post-operative complications and to guide timely interventions.

“The early detection is expected to allow faster intervention and prevention of complications after the surgery.”

“Effective monitoring systems are necessary in order to reduce the number of painful and care-intensive complications after surgery.”

Being conducted at the Uppsala University Hospital, the trial will use the system to assess the local lactate levels in esophageal cancer patients after surgery, for early identification of signs of leakage before detection by standard diagnostics.

It is reported that initial assessments from the trial are expected to be revealed after enrolling 20 patients.

The early detection is expected to allow faster intervention and prevention of complications after the surgery.

Image: CliniSenz Analyzer. Photo: courtesy of Senzime.